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Abstract Despite tremendous research efforts, type 1 diabe-
tes is one of the few remaining autoimmune diseases without
any approved immunological treatment. This observation
compels us to reconsider the role of autoimmunity in the
pathogenesis of this disease. In this commentary, we will
review solely human data in an attempt to appreciate, in an
unbiased manner, the importance and relevance of the immu-
nological alterations in patients with type 1 diabetes. The aim
of this paper is to generate reflection on this topic, rather than a
controversy.
Keywords Autoimmunity . Beta cells . Clinic .
Type 1 diabetes
A recent expert workshop reviewed the histopathological
characteristics of insulitis in human type 1 diabetes [1]. It
was noted that, in humans, only 150–200 cases have been
described. The emerging picture of insulitis (described in the
consensus definition of insulitis) is that the fraction of infil-
trated islets is very low (<10%), and the infiltrated islets
contain very few immune cells (≥15 leucocytes/islet is con-
sidered as positive for infiltration, which is only twice the
number of leucocytes found in control donor pancreases [2]).
Moreover, infiltrating leucocytes are often found only in the
islet periphery (peri-insulitis). Although islet-autoreactive
CD8+ T cells were detected [3], the level of insulitis remains
surprisingly mild, even in patients with recent-onset type 1
diabetes and death due to ketoacidosis [4]. This picture is
complicated by background infiltration in the exocrine pan-
creas, partly due to peri-mortem changes, with the highest
levels of infiltration observed in young patients after
prolonged life support [5]. Even independently of post-
mortem changes, type 1 diabetes affects the exocrine as well
as the endocrine pancreas [6]; this raises the question whether
the limited infiltration of leucocytes is specifically targeted to
pancreatic beta cells. Moreover, this limited degree of cellular
infiltration in human autopsy samples is in striking contrast to
NOD mice, which display massive leucocyte infiltration,
reflecting the well-documented immune-mediated destruction
of the beta cells in this animal model. Interestingly, the cellular
infiltrates observed in NOD mouse islets are reminiscent of
histopathological findings in organs affected by ‘classical’
human autoimmune diseases, such as rheumatoid arthritis,
psoriasis, arteritis and colitis (see e.g. Lahmar et al [7]). Even
strictly antibody-mediated autoimmunity, such as the anti-
glomerular basement syndrome, is accompanied by a relevant
influx of inflammatory leucocytes [8]. Therefore, based on the
available human histological findings in patients with type 1
diabetes, it is difficult to relate such a mild immune cell
infiltration to the devastating consequences on insulin secre-
tion observed in the clinic.
Even more puzzling is the outcome of clinical studies in
patients with type 1 diabetes: although encouraging, they need
to be put into context. The ciclosporin trials are often quoted
as proof of concept studies, demonstrating the autoimmune
nature of the disease [9, 10]; however, several limitations
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question such a definitive conclusion and, indeed, the absolute
number of responders was low. In one study, only 25.4% of
the ciclosporin group vs 18.6% of the placebo group were in
complete remission at 6 months, which is not statistically
significant; only sub-analyses showed statistically significant
differences [10]. A follow-up study did achieve statistical
significance with a higher rate of remission, but in absolute
terms the efficacy remained rather modest (33% remission
with ciclosporin compared with 22% with placebo) [9]. Of
note, in both studies ciclosporin treatment did not translate
into improvement in HbA1c levels. Furthermore, the appear-
ance of hypertrichosis and gingival hyperplasia (both typical
side effects of ciclosporin treatment) indirectly unblinded the
study. Other untoward effects such as abdominal discomfort,
nausea, vomiting, diarrhoea and infections, or off-target ef-
fects, may also explain, at least in part, the metabolic effects of
ciclosporin on diabetes—independent of its immunosuppres-
sive effects. The lack of a temporal correlation between chang-
es in islet cell antibodies and changes in C-peptide levels are
also in line with this supposition [11]. Indeed, this observation
has given rise to the hypothesis that the generation of auto-
antibodies in type 1 diabetes may be a secondary event trig-
gered by a primary islet-destructive process. Follow-up stud-
ies using other immune modulatory treatments, including
cytotoxic T-lymphocyte antigen 4 (CTLA4)–immunoglobulin
fusion protein [12], anti-CD20 antibody [13], anti-CD3 anti-
body [14–16], DiaPep277 [17], TNF-α receptor fusion pro-
tein [18] and anti-IL-1β antibody or IL-1 receptor antagonist
[19], showed mild initial benefit, or no benefit at all. Of note,
in cases where clinical benefits were observed, the typical
pattern was an initial improvement in insulin production,
followed by a decline which paralleled that observed in un-
treated patients. Taken together, these data suggest that dele-
terious effects on beta cell function attributable to the immune
system are small, and that a separate pathogenic mechanism is
the main driving force of beta cell loss. The limited and partial
improvement observed in patients with type 1 diabetes con-
trasts with the profound benefit observed with similar treat-
ments in other autoimmune diseases; see for example that
TNF-α antagonism in Crohn’s disease induces a response in
80% of cases compared with 17% in placebo-treated patients
[20]. Of note, the lack of efficacy of immunomodulatory
therapy in patients with type 1 diabetes cannot be attributed
to the timing of therapeutic intervention, because most studies
were performed within 3 months after the onset of
hyperglycaemia, a time point when there is still sufficient beta
cell mass present that could potentially be rescued [21].
Indeed, most patients experience a spontaneous remission
for weeks or months following the initial onset of
hyperglycaemia (referred to as the ‘honeymoon’), which is
possibly caused by a reversal of glucotoxicity. Therefore, the
time and duration of the immune intervention (several months
in most trials) should have been sufficient to achieve similar
effects to those occurring naturally during the honeymoon.
However, our speculation should in no way discourage ongo-
ing or planned clinical studies evaluating the above-
mentioned or other immune modulating drugs: future studies,
using other designs or combinations of drugs may prove us
wrong.
In some patients, type 1 diabetes is associated with other
autoimmune disease. This association is often put forward as
an argument for an autoimmune aetiology of type 1 diabetes.
Nevertheless, this association is not a general trait of type 1
diabetes, but the situation is rather that a small fraction of type
1 diabetes cases are associated with very specific diseases,
mainly Hashimoto's thyroiditis, adrenal insufficiency, vitiligo
and coeliac disease. To explain such an association by a defect
in the adaptive immune system, one might expect somemech-
anism that would target the immune system specifically to
these different tissues. Yet at molecular level, there is no
obvious similarity between the affected tissues, for example
the steroid-producing adrenal cells and the peptide hormone-
releasing beta cells. However, it is noteworthy that all the
above-mentioned diseases affect active, secretory cells. There-
fore, it is conceivable that the primary shared defect is a
secretory dysfunction (possibly inherited) leading to cell de-
struction. As a secondary event, excessive auto-antigen pre-
sentation will occur and peripheral tolerance may eventually
be lost. Indeed, a pathological activation of the immune sys-
tem is observed in most patients with type 1 diabetes, as
reflected by the presence of auto-antibodies and T cells
targeting beta cell-derived antigens. Nevertheless, such acti-
vation is also observed in many diseases involving cell death,
including type 2 diabetes [22]. Thus, the question is whether
these immunological phenomena are the main drivers, or
merely epiphenomena, in the pathogenesis of type 1 diabetes.
The strong linkage of type 1 diabetes with HLA genotype
favours an autoimmune aetiology [23]. However this cannot
be considered as a final proof, since this chromosomal region
encodes hundreds of genes, which may also be involved in
beta cell demise by other mechanisms. Furthermore, type 1
diabetes does not segregate with any clear mode of inheri-
tance. Along the same lines, the interesting observation that
recurrence of disease has been prevented by immunosuppres-
sion in a few cases of recipients of monozygotic twin semi-
pancreatic grafts [24] may point to an autoimmune aetiology,
but the incomplete description of the immunological reaction
and the complex setting of organ transplantation do not rule
out other causes.
Thus we are left to ponder the true nature of the disease.
Adding to the complexity of this issue is the heterogeneity
between patients and the histological heterogeneity within any
given pancreas [1], most probably reflecting distinct subtypes
of diabetes. It is conceivable that true autoimmunity occurs in
a subtype of patients; however, both in the histopathology
studies and in the clinical trials discussed above, cases with
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marked leucocyte infiltration or with remission following
immunosuppressive treatment are rare. Therefore, we believe
that an open-minded effort should be made to understand the
primary aetiology of type 1 diabetes, instead of focusing on
downstream events and pathways that may or may not be
relevant. The Network for Pancreatic Organ Donors with
Diabetes initiative, supported by the JDRF, has led to the
above-mentioned review of human pancreas histology [1];
this is a step in right direction.
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